Canadian Clinical Trial Summit

On September 15, 2011 Rx&D, CIHR and ACAHO launched the National Clinical Trials Summit which has now resulted in an action plan to Help Attract More Clinical Trials to Canada.   Over a year later, the effort continues.
 
On this webpage, readers will find the following related materials.
  1. Towards Health & Prosperity – A 1st year Communiqué on Progress since the 2011 Summit & release of the action plan Action Plan (updated as at December 2012)
  2. To Your Health & Prosperity: An Action Plan to Help Attract More Clinical Trials to Canada (Action Plan)
  3. Towards an Action Plan – Proceedings of 2011 National Clinical Trials Summit
  4. National Clinical Trials Summit – Keynote and breakout room presentations
  5. Starting the Conversation – National Clinical Trials Summit (background paper)
Towards Health & Prosperity – A 1st Year Communiqué on the Action Plan and on the 6 months since the national clinical trials summit.
 
At the first anniversary of the 2011 Clinical Trials Summit, ACAHO, Rx&D and CIHR reflect on the year since the 2011 Summit and give a six month progress report since the Action Plan’s release. The collective commitment to action and the sincerity of stakeholders in mobilizing positive changes in the clinical trials landscape is evidenced by the efforts of many.
 
Read the Update from CIHR, Rx&D and ACAHO
 
Read the Addendum from Provincial Clinical Trial bodies
 
To Your Health & Prosperity – An Action Plan to Health Attract More Clinical Trials to Canada
 
To Your Health & Prosperity - An Action Plan to Help Attract More Clinical Trials to Canada is the action plan from the 2011 National Clinical Trials Summit. It is the third and final paper in a trilogy of papers from the clinical trial summit hosted by Rx&D, CIHR, and ACAHO.  It reflects a vision for Canada as a premier country for industry led clinical trials. The goals of the action plan are to help halt and reverse a downward investment trend, improve overall business practices as they pertain to clinical trial start up times, and present a forward looking business opportunity through information and incentives for global companies. The action plan contains nine recommendations in three strategies. The first recommendation encapsulates its implementation through potential alignment with the Strategy for Patient Oriented Research (SPOR). This final version of the action plan also contains an appendix which reflects feedback given on the final draft. This feedback is largely supportive and also instructional as it pertains to the implementation of this plan. AS such, it is considered part of the final document.  A one page summary is also available. 

Towards an Action Plan – Proceedings from the 2011 Clinical Trials Summit (Proceedings)

Towards an Action Plan - Proceedings from the 2011 Clinical Trials Summit  is the second in a trilogy of papers from the September 2011 Clinical Trials Summit co-hosted by Rx&D, CIHR and ACAHO. The goal of the summit was to enable development of an action plan that will help Canada regain capacity to attract clinical trial opportunities. The proceedings reflect a day long discussion with 130 experts from various sectors on how to improve cost, quality, speed and relationships as they pertain to clinical trial start up times and other issues. They include discussion notes from break out rooms on streamlining ethics reviews, patient recruitment, facilitating administrative issues, cost issues, and strategic infrastructure. The proceedings include interpretation of the comments into potential actionables. These actionables were circulated to delegates in November for feedback which now appears in an Appendix. They will form the basis of the action plan that will be presented as the third and final document in the trilogy of papers from the Clinical Trials Summit.

Keynote Presentations

Break Out Room Presentations

  • Ethics Review
    Linda Barrett-Smith, Director, Research Ethics & Alberta Clinical Research Consortium (ACRC)
    Dr. Stanislav Glezer, Vice-President Medical Affairs, sanofi-aventis
  • Recruitment & Retention 
    Diane Simmons, President and CEO, Center for Information and Study on Clinical Research Participation
    Sandra Gazel, Associate Director, Clinical Operations, Abbott
  • Admininstrative Issues 
    Dr. Neil Maresky, Vice-President, Scientific Affairs, AstraZeneca Inc.
    Karen Arts, Director, Business Development, Clinical Trials, Ontario Institute for Cancer Research & Co-Founder and Chair of Board of Directors Network of Networks (N2)
  • Cost Issues 
    Linda Bennett, Executive Director, Canadian Rheumatology Research Consortium
    Dr. Shurjeel Choudhri, Senior Vice-President and Head, Medical and Scientific Affairs, Bayer Inc.

Backgrounder Document

You can access the background document here.

Read media perspectives, editorials and journal articles related to the Summit and Action Plan